Osivax pivots to combo approach after flu jab fails in Phase 2b
Osivax’s lead flu vaccine has flopped in a mid-stage trial. But the French biotech still holds out hope for the program, and plans to combine it with existing flu shots. The Phase 2b trial aimed ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.